ClinicalTrials.gg
CompletedNCT02578797Updated Nov 9, 2023

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

A Phase 1 interventional study of Apalutamide in Castration-Resistant Prostate Cancer, sponsored by Aragon Pharmaceuticals, Inc.. Completed at 5 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.

Enrollment
47th of 70
45 · median 81
Started
2015
with 2 others
Phase 1
11 of 70
1 open now
Registered
10th of 70
by date
Lead sponsor
9 of 70
Aragon Pharmaceuticals, Inc.

Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 47th largest by enrollment, is one of 3 that started in 2015, is one of 11 in phase 1, and was the 10th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apalutamide

apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing apalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether daily treatment with apalutamide affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC)

Read the detailed description

This is an open-label (a study in which the drug, procedure is known to participant and investigator), multicenter, Phase 1b study to investigate the effect of apalutamide on ventricular repolarization at a dose level of 240 milligram (mg daily). Approximately 42 participants with high-risk non-metastatic prostate cancer (NM-CRPC), defined as having a prostate specific antigen (PSA) doubling time less than or equal to (\<=) 10 months, or participants with metastatic CRPC will be enrolled. The study consists of a 28-day Screening Phase, a Treatment Phase and a Follow-up Phase. In the Treatment Phase the study drug will be administrated in cycles of 28 days and the participants will be monitored for safety (including cardiac safety) and pharmacokinetics of the study drug. Adverse Events will be monitored throughout the study and in the Follow-up Phase until 30 days after the last dose of study drug. All participants will continue on study until disease progression, withdrawal of consent, lost to follow-up, the occurrence of unacceptable toxicity, the participant is no longer receiving clinical benefit in the opinion of the investigator, or termination of the study by the sponsor. Upon discontinuation of study drug, the participants will return for an End-of-Treatment (EoT) visit no later than 30 days after their last dose. The end of the study corresponds to the clinical cutoff and end of data collection.

03

Conditions studied

  • Castration-Resistant Prostate Cancer

Keywords

  • Castration-Resistant Prostate Cancer (CRPC)
  • Prostatic Neoplasms
  • Genital Diseases, Male
  • Genital Neoplasms, Male
  • Neoplasms
  • Neoplasms by Site
  • Prostatic Diseases
  • Urogenital Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status score of 0 or 1
  • Adenocarcinoma of the prostate; either non- castrate resistant prostate cancer (NM-CRPC) with high risk disease (defined as PSA Doubling time equal or less than (\<=) 10 months) or metastatic CRPC
  • Be surgically or medically castrated with testosterone levels of less than (\<) 50 nanogram per deciliter
  • If treated with a gonadotropin releasing hormone analog (ie, patient who has not undergone bilateral orchiectomy), then this therapy must have been initiated at least 4 weeks prior to Cycle 1 Day 1 and must be continued throughout the study
  • (ECG) showing a corrected for heart rate, using Fridericia formula (QTcF) \<= 470 milliseconds (based on the average of a triplicate ECG set collected during the screening visit)
  • (LVEF) of more than 45% as determined by multiple uptake gated acquisition (MUGA) or echocardiography at the screening visit

Exclusion criteria

Exclusion Criteria:

  • Abnormal cardiac function at screening
  • Known
  • Has received an drug within 4 weeks, or within a period \< 10 times the drug's half-life, whichever is longer, of Cycle 1 Day 1
  • Has received chemotherapy or immunotherapy for the treatment of prostate cancer within 4 weeks of Cycle 1 Day 1
  • Prior treatment with enzalutamide and apalutamide
  • Use of therapies that must be discontinued or substituted within at least 4 weeks prior to Cycle 1 Day 1 including medications to lower seizure threshold, inducing/inhibiting metabolizing enzymes or prolonging the
  • History or condition that may predispose to seizures, or evidence of severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events within 12 months prior to Cycle 1 Day 1, (NYHA) Class II to IV heart disease
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Apalutamide

    Prostate Cancer participants will receive the study drug on an outpatient basis except for Cycle 1 (Day 1 and Day 2) and Cycle 3 (Day 1), when intake must occur at study site under overnight fasted conditions.

    Drug: Apalutamide

Interventions

  • Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.

06

What researchers measure

Primary outcomes

  1. QTc Fridericia (QTcF) parameter

    Mean change from baseline in QTcF as measured based on triplicate electrocardiograms extracted from continuous 12-lead Holter monitor recordings after study drug intake.

    Time frame: Day-1 and Day 1 (Cycle 1) and Day 1 (Cycle 3)

Secondary outcomes

  1. Electrocardiographic parameters (HR, RR, PR, and QRS)

    A change from time-matched baseline measurements in HR, PR, RR and QRS interval will be determined on Day -1, Day 1 and Day 3

    Time frame: Day-1 and Day 1 (Cycle 1) and Day 1 (Cycle 3)

  2. Electrocardiographic parameters (QT)

    QT interval on a surface ECG will be corrected for heart rate using Bazett formula (QTcB) and study-specific Power (QTcP) if appropriate at each treatment period.

    Time frame: Day-1 and Day 1 (Cycle 1) and Day 1 (Cycle 3)

  3. Electrocardiographic parameters T- and U-wave morphology

    Number and percentage of participants with changes from baseline

    Time frame: Day-1 and Day 1 (Cycle 1) and Day 1 (Cycle 3)

  4. Plasma concentrations apalutamide (and its active metabolite JNJ-56142060)

    Blood samples will be taken following dose administration.

    Time frame: Day-1, Day 1 and Day 2 (Cycle 1) and Day 1 (Cycle 3)

  5. Number of participants with Adverse Events

    Participants will be monitored for safety during the Screening and Treatment Phases, and up to 30 days after the last dose of study drug. From Cycle 4 onward collection of Adverse Events (AEs) will be limited to Grade 3 or higher and all Serious AEs from the remainder of the study.

    Time frame: Day-1, Day 1 and Day 15 (Cycle 1); Day 1 and Day 15 (Cycle 2) and Day 1 (Cycle 3).

  6. Pharmacokinetic parameter area under the plasma drug concentration-time curve (AUC) from time 0 to 24 hours

    The AUC(0-24h) is the area under the plasma concentration-time curve from time 0 to time 24 hours after dosing.

    Time frame: Day 1 and Day 2 (Cycle 1) and Day 1 (Cycle 3)

  7. Pharmacokinetic parameter maximum concentration observed (Cmax)

    The Cmax is the maximum observed plasma concentration.

    Time frame: Day 1 and Day 2 (Cycle 1) and Day 1 (Cycle 3)

  8. Pharmacokinetic parameter time to reach Cmax (tmax)

    The tmax is the time to reach the maximum observed plasma concentration.

    Time frame: Day 1 and Day 2 (Cycle 1) and Day 1 (Cycle 3)

  9. Pharmacokinetic parameter minimum observed plasma concentration (Cmin)

    The Cmin is the minimum observed plasma concentration.

    Time frame: Cmin will only be collected on Day 1, Cycle 3

07

Study locations

5 sites
  • Greenville, South Carolina, United States
  • Montreal, Quebec, Canada
  • Chisinau, Moldova, Republic of
  • Rotterdam, Netherlands
  • Sutton, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Sep 2016, 9 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 9 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2015
First posted
Oct 19, 2015
StartActual
Dec 18, 2015
Primary completionActual
Sep 20, 2016
CompletionActual
Oct 13, 2022
Last update
Nov 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02578797
Responsible party
Sponsor
First posted
Oct 19, 2015
Start date
Dec 18, 2015
Primary completion
Sep 20, 2016
Completion
Oct 13, 2022
Last update
Nov 9, 2023

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apalutamide

Start the discussion